166
Participants
Start Date
May 31, 2014
Primary Completion Date
January 19, 2018
Study Completion Date
May 16, 2018
Bardoxolone methyl
Placebo
Mount Sinai, Beth Israel Medical Center, New York
Weill Cornell Medical Center, New York
Winthrop University Hospital, Mineola
University of Rochester - University of Rochester Medical Center, Rochester
University of Pittsburgh Medical Center, Pittsburgh
Georgetown University Medical Center - Department of Rheumatology, Washington D.C.
Universitaetsklinikum Hamburg-Eppendorf, Hamburg
Cleveland Clinic of Florida, Weston
The Ohio State University Wexner Medical Center, Columbus
The Lindner Clinical Trial Center, Cincinnati
University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine, Cincinnati
University of Chicago, Chicago
Oklahoma Heart Hospital, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
Houston Methodist Research Institute, Houston
The University of Texas - Health Science Center & Medical School at Houston, Houston
University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
BreatheAmerica El Paso, Inc., El Paso
University of Colorado Denver - Division of Pulmonary Sciences, Aurora
South Denver Cardiology Associates, P.C, Littleton
University of Utah, Salt Lake City
Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix
Arizona Pulmonary Specialists, Phoenix
VA Healthcare System of Greater Los Angeles, Los Angeles
Cedars Sinai Medical Center, Beverly Hills
Harbor - UCLA Medical Center, Torrance
University of California Davis Medical Center - Division of Pulmonary and Critical Care, Sacramento
Maine Medical Center - Division of Pulmonary and Critical Care Medicine, Portland
Tufts Medical Center, Boston
Brigham and Women's Hospital, Boston
Boston University School of Medicine, Boston
University Clinic Carl Gustav Carus, Dresden
Lead Sponsor
Biogen
INDUSTRY